e-therapeutics logo

e-therapeutics: Computing the Future of Medicine

Biotechnology Research

NYSE:ETX
$18.17-0.27%
Updated: May 02, 2025

Executive Summary

Computing the future of medicine

e-therapeutics is a UK biotech using its innovative computational biology and RNAi chemistry to identify novel gene targets and rapidly develop RNAi therapies that specifically target genes in the liver. ETX’s HepNet platform is a well-established AI-driven drug discovery platform that gets new drugs to market faster, cheaper and with an increased probability of success. It’s the type of strategic asset that is likely to interest numerous big pharma companies in the future as it could transform treatment paradigms across multiple diseases, particularly those with few current treatment options.
Investor Relations

Investment Thesis

Overview of buy and sell case of the business.

Why Invest?

Key pieces of information about the business that you need to know about.

The Mission

Investors are attracted to the speed and cost efficiency of the process. Embedding computational and AI technologies into every aspect of the R&D process helps overcome the high costs and lengthy timelines typically associated with developing new drugs for patients. e-therapeutics can deliver a drug from concept to proof-of-concept within a year, for just £1m versus typical industry cost of at least £5-10m.

Industry Leader

e-therapeutics embeds computational and AI technologies into every aspect of the R&D process to enhance drug discovery. Their use of AI-driven technology can accelerate target identification, enhance the quality of drug discovery, allows for more precise and data-driven decisions and therefore contributes to the rapid advancement of their drug pipeline.

Novel pipeline

e-therapeutics has a novel and highly differentiated drug pipeline focused on RNA interference (RNAi) therapeutics that sets it apart from competitors. The two leading candidates in their pipeline, ETX-407 for dAMD and ETX-312 for MASH, are progressing towards clinical trials.

Catalysts

The key events that could drive investment opportunities and shift markets.

Near term
Near term
Medium term
Medium term
Long term
Long term

Follow the Experts

Quickly navigate key insights from industry experts and leverage their knowledge and market intelligence.

Dr. Craig Mello profile

Dr. Craig Mello

Molecular biologist

1k audience

Expert Insights

youtube
RNA science could change our lives
See more
Arrowhead Pharmaceuticals profile

Arrowhead Pharmaceuticals

biopharmaceutical company

42k audience

Expert Insights

article
RNAi offers the ability to target a broad range of genes, and to do so with high specificity.
Read here
Alnylam Pharmaceuticals profile

Alnylam Pharmaceuticals

RNAi therapeutics - developed first FDA-approved RNAi drug

202k audience

Expert Insights

linkedin
RNA interference (RNAi) is a naturally occurring process of gene regulation that is already at work inside your body. RNAi therapeutics utilize this process to silence the genes that cause or contribute to disease
see more
RNA Therapeutics Institute profile

RNA Therapeutics Institute

RNA biology and clinical research department

2k audience

Expert Insights

article
Novel siRNA backbone developed at UMass Chan enhances stability, durability of potentially therapeutic platform
Read here
article
Since RNA is so central to many basic life processes, any new therapeutic approach developed by RTI researchers could potentially be applied to a wide variety of problems.
See more
linkedin
RNA silencing complex is globally disrupted by single amino acid changes
See more
Dirk Haussecker profile

Dirk Haussecker

Independent Analyst, RNAi Therapeutics

18k audience

Expert Insights

article
12 years following the discovery of the RNAi, a number of RNAi therapeutics development candidates have emerged with profiles suggesting they could become drugs of significant medical importance for diseases.
See more
article
The RNAI Therapeutics Blog
Follow Here
Dr. Phillip Zamore profile

Dr. Phillip Zamore

molecular biologist and biochemist

470 audience

Expert Insights

article
The Zamore Laboratory studies the biology, mechanisms, and evolution of Argonaute proteins – an ancient family of proteins that plays a central role in RNA silencing processes
See more
youtube
"The way the siRNA drugs are designed are incredibly stable and have fewer side effects"
See More

Investor Materials

Access the most recent investor updates published by the company.

Key Investor Materials

Press releases

Article

Filing of four new patent applications

Investor Presentation Feb 2024

PDF

External Insights

A curated collection of third-party content relevant to the company and sector to help inform your investment decision.

AI & Drug Discovery

How to enable AI in drug discovery where there's no big data | Tian Cai | TEDxBoston

Article

Enjoy the videos and music that you love, upload original content and share it all with friends, family and the world on YouTube.

RNAi

20th Anniversary of RNA Interference in Mammalian Cells - Oligonucleotide Therapeutics Society

Article

The groundbreaking discovery of RNA interference by Craig Mello and Andrew Fire was swiftly followed by the discovery of RNAi as a gene-silencing mechanism in mammalian cells. Since these breakthroughs, members of our community have devoted their lives to building on these exciting discoveries, and together we are producing results that greatly improve the quality

Team

Meet the experienced professionals leading our organization

What the Pro's Are Asking

Here are the questions that professional investors are asking before making an investment decision.

Why should investors care about ETX?

e-therapeutics offers the opportunity to invest in a competent team that is delivering a promising future modality, underpinned by a proven business model and supported by Artifical Intelligence across the entire value chain. e-therapeutics can deliver a drug from concept to proof-of-concept within a year, for just £1m versus typical industry cost of at least £5-10m.

What challenges is ETX facing?

Firstly, geopolitical issues worldwide have put pressure on delivery timelines and pricing, due to the increase in costs of raw materials globally.

Secondly, Bio-technology sector is undergoing a correction leading to more cautious behaviour by potential partners and investors in the near-term.

Have you validated your computational platform?

Yes, e-therapeutics' computational platform has successfully identified gene-disease pairs and has subsequently shown significant positive data to prove safety and efficacy of those drugs.

How does ETX plan to finance future clinical trials?

The future trajectory involves partnership deals across the various pre-clinical and clinical stages for individual therapeutic candidates, which can help to mitigate the need to raise dilutive capital.

What diseases are you looking to address?

While e-therapeutics primarily targets liver-related diseases, its scope extends beyond the liver, using the connection it shares with vital organs. These connections open opportunities for potential treatments in areas such as eye disease and heart disease. Additionally, e-therapeutics hold the potential to cure metabolic diseases, including diabetes, metabolic syndrome and cardio-metabolic disorders, showing the endless opportunities outside the liver.